chlorambucil has been researched along with Myeloproliferative Disorders in 10 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A splenectomized patient with hairy cell leukemia (HCL) who had received chemotherapy with a low-dose alkylating agent for 2 years developed dysmyelopoietic syndrome (DMPS), the first such case to be described." | 5.27 | Development of dysmyelopoietic syndrome in a hairy cell leukemia patient treated with chlorambucil: cytogenetic and morphologic evaluation. ( Albain, KS; Golomb, HM; Le Beau, MM; Rowley, JD; Vardiman, JW, 1983) |
| "One of the MPDs, chronic myeloid leukemia (CML), has the distinct cytogenetic abnormality of the Philadelphia chromosome." | 2.42 | Treatment paradigms in the management of myeloproliferative disorders. ( Fruchtman, SM, 2004) |
| "Its use in the treatment of essential thrombocythemia began later in 1950." | 2.41 | Treatment of the myeloproliferative disorders with 32P. ( Berlin, NI, 2000) |
| "Three of four patients with Hodgkin's disease responded after relatively short periods of treatment." | 1.27 | Leukocyte interferon as a possible biological response modifier in lymphoproliferative disorders resistant to standard therapy. ( Axelson, JA; Charamella, LJ; Clark, RH; Dimitrov, NV, 1984) |
| "A splenectomized patient with hairy cell leukemia (HCL) who had received chemotherapy with a low-dose alkylating agent for 2 years developed dysmyelopoietic syndrome (DMPS), the first such case to be described." | 1.27 | Development of dysmyelopoietic syndrome in a hairy cell leukemia patient treated with chlorambucil: cytogenetic and morphologic evaluation. ( Albain, KS; Golomb, HM; Le Beau, MM; Rowley, JD; Vardiman, JW, 1983) |
| "Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow." | 1.27 | Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. ( Ersbøll, J; Keiding, N; Larsen, MS; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Philip, P; Schultz, H; Sørensen, HM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fruchtman, SM | 1 |
| Clark, RH | 1 |
| Dimitrov, NV | 1 |
| Axelson, JA | 1 |
| Charamella, LJ | 1 |
| Sølling, K | 1 |
| Nielsen, JL | 1 |
| Sølling, J | 1 |
| Ellegaard, J | 1 |
| Albain, KS | 1 |
| Le Beau, MM | 1 |
| Vardiman, JW | 1 |
| Golomb, HM | 1 |
| Rowley, JD | 1 |
| Berlin, NI | 1 |
| Silverstein, MN | 1 |
| Maurice, P | 1 |
| Pedersen-Bjergaard, J | 1 |
| Ersbøll, J | 1 |
| Sørensen, HM | 1 |
| Keiding, N | 1 |
| Larsen, SO | 1 |
| Philip, P | 1 |
| Larsen, MS | 1 |
| Schultz, H | 1 |
| Nissen, NI | 1 |
| Lewis, SM | 1 |
| Szur, L | 1 |
| Gilbert, HS | 1 |
| Krauss, S | 1 |
| Pasternack, B | 1 |
| Herbert, V | 1 |
| Wasserman, LR | 1 |
2 reviews available for chlorambucil and Myeloproliferative Disorders
| Article | Year |
|---|---|
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, | 2004 |
Treatment of the myeloproliferative disorders with 32P.
Topics: Adult; Aged; Alkylating Agents; Chlorambucil; Clinical Trials as Topic; Combined Modality Therapy; D | 2000 |
8 other studies available for chlorambucil and Myeloproliferative Disorders
| Article | Year |
|---|---|
Leukocyte interferon as a possible biological response modifier in lymphoproliferative disorders resistant to standard therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Chlorambucil; Female; Hodgki | 1984 |
Free light chains of immunoglobulins in serum from patients with leukaemias and multiple myeloma.
Topics: Adolescent; Adult; Aged; Child; Chlorambucil; Humans; Immunoglobulin kappa-Chains; Immunoglobulin la | 1982 |
Development of dysmyelopoietic syndrome in a hairy cell leukemia patient treated with chlorambucil: cytogenetic and morphologic evaluation.
Topics: Bone Marrow; Chlorambucil; Chromosome Aberrations; Humans; Karyotyping; Leukemia, Hairy Cell; Male; | 1983 |
Myeloproliferative diseases.
Topics: Adult; Aged; Chlorambucil; Female; Humans; Male; Melphalan; Middle Aged; Myeloproliferative Disorder | 1977 |
[The treatment of myeloproliferative syndromes].
Topics: Aged; Bloodletting; Busulfan; Chlorambucil; Female; Humans; Leukemia, Myeloid; Male; Myeloproliferat | 1975 |
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Topics: Acute Disease; Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Prot | 1985 |
Blood and neoplastic diseases. Myeloproliferative disorders.
Topics: Adrenal Cortex Hormones; Androgens; Blood Transfusion; Bloodletting; Busulfan; Chlorambucil; Cycloph | 1974 |
Serum vitamin B12 content and unsaturated vitamin B12-binding capacity in myeloproliferative disease. Value in differential diagnosis and as indicators of disease activity.
Topics: Adult; Aged; Blood Proteins; Bloodletting; Chlorambucil; Chromatography; Cyclophosphamide; Diagnosis | 1969 |